FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011766387> ?p ?o ?g. }

• W2011766387 endingPage "e57479" @default.
• W2011766387 startingPage "e57479" @default.
• W2011766387 abstract "In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bispecific IgG antibodies to factor IXa (FIXa) and factor X (FX), mimicking the FVIII cofactor function. Since the therapeutic potential of the lead bispecific antibody was marginal, FVIII-mimetic activity was improved by modifying its binding properties to FIXa and FX, and the pharmacokinetics was improved by engineering the charge properties of the variable region. Difficulties in manufacturing the bispecific antibody were overcome by identifying a common light chain for the anti-FIXa and anti-FX heavy chains through framework/complementarity determining region shuffling, and by pI engineering of the two heavy chains to facilitate ion exchange chromatographic purification of the bispecific antibody from the mixture of byproducts. Engineering to overcome low solubility and deamidation was also performed. The multidimensionally optimized bispecific antibody hBS910 exhibited potent FVIII-mimetic activity in human FVIII-deficient plasma, and had a half-life of 3 weeks and high subcutaneous bioavailability in cynomolgus monkeys. Importantly, the activity of hBS910 was not affected by FVIII inhibitors, while anti-hBS910 antibodies did not inhibit FVIII activity, allowing the use of hBS910 without considering the development or presence of FVIII inhibitors. Furthermore, hBS910 could be purified on a large manufacturing scale and formulated into a subcutaneously injectable liquid formulation for clinical use. These features of hBS910 enable routine prophylaxis by subcutaneous delivery at a long dosing interval without considering the development or presence of FVIII inhibitors. We expect that hBS910 (investigational drug name: ACE910) will provide significant benefit for severe hemophilia A patients." @default.
• W2011766387 created "2016-06-24" @default.
• W2011766387 creator A5005341632 @default.
• W2011766387 creator A5010205635 @default.
• W2011766387 creator A5010392419 @default.
• W2011766387 creator A5012870792 @default.
• W2011766387 creator A5012938382 @default.
• W2011766387 creator A5013907733 @default.
• W2011766387 creator A5037618983 @default.
• W2011766387 creator A5048265991 @default.
• W2011766387 creator A5050283922 @default.
• W2011766387 creator A5052742879 @default.
• W2011766387 creator A5054454647 @default.
• W2011766387 creator A5056916028 @default.
• W2011766387 creator A5067451452 @default.
• W2011766387 creator A5068218209 @default.
• W2011766387 creator A5070709942 @default.
• W2011766387 creator A5073497321 @default.
• W2011766387 creator A5074604445 @default.
• W2011766387 creator A5075660409 @default.
• W2011766387 creator A5083483473 @default.
• W2011766387 date "2013-02-28" @default.
• W2011766387 modified "2023-10-18" @default.
• W2011766387 title "Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity" @default.
• W2011766387 cites W1497014448 @default.
• W2011766387 cites W1555185942 @default.
• W2011766387 cites W1572809479 @default.
• W2011766387 cites W1890969760 @default.
• W2011766387 cites W1902060432 @default.
• W2011766387 cites W1965205681 @default.
• W2011766387 cites W1966286047 @default.
• W2011766387 cites W1968924601 @default.
• W2011766387 cites W1971242419 @default.
• W2011766387 cites W1978261191 @default.
• W2011766387 cites W1985562310 @default.
• W2011766387 cites W1986852088 @default.
• W2011766387 cites W1989839638 @default.
• W2011766387 cites W1993159801 @default.
• W2011766387 cites W1993800425 @default.
• W2011766387 cites W2000144429 @default.
• W2011766387 cites W2001483547 @default.
• W2011766387 cites W2008513453 @default.
• W2011766387 cites W2020908798 @default.
• W2011766387 cites W2029669166 @default.
• W2011766387 cites W2030085576 @default.
• W2011766387 cites W2033439473 @default.
• W2011766387 cites W2045886098 @default.
• W2011766387 cites W2075097399 @default.
• W2011766387 cites W2085020697 @default.
• W2011766387 cites W2091229935 @default.
• W2011766387 cites W2092720388 @default.
• W2011766387 cites W2098951552 @default.
• W2011766387 cites W2102686641 @default.
• W2011766387 cites W2104198642 @default.
• W2011766387 cites W2108803513 @default.
• W2011766387 cites W2119768870 @default.
• W2011766387 cites W2126075421 @default.
• W2011766387 cites W2136551605 @default.
• W2011766387 cites W2138554147 @default.
• W2011766387 cites W2138914609 @default.
• W2011766387 cites W2140440388 @default.
• W2011766387 cites W2148612170 @default.
• W2011766387 cites W2150732944 @default.
• W2011766387 cites W2155130452 @default.
• W2011766387 cites W2167801052 @default.
• W2011766387 cites W2167864435 @default.
• W2011766387 cites W2171594570 @default.
• W2011766387 cites W4238520503 @default.
• W2011766387 cites W72493355 @default.
• W2011766387 doi "https://doi.org/10.1371/journal.pone.0057479" @default.
• W2011766387 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3585358" @default.
• W2011766387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23468998" @default.
• W2011766387 hasPublicationYear "2013" @default.
• W2011766387 type Work @default.
• W2011766387 sameAs 2011766387 @default.
• W2011766387 citedByCount "226" @default.
• W2011766387 countsByYear W20117663872014 @default.
• W2011766387 countsByYear W20117663872015 @default.
• W2011766387 countsByYear W20117663872016 @default.
• W2011766387 countsByYear W20117663872017 @default.
• W2011766387 countsByYear W20117663872018 @default.
• W2011766387 countsByYear W20117663872019 @default.
• W2011766387 countsByYear W20117663872020 @default.
• W2011766387 countsByYear W20117663872021 @default.
• W2011766387 countsByYear W20117663872022 @default.
• W2011766387 countsByYear W20117663872023 @default.
• W2011766387 crossrefType "journal-article" @default.
• W2011766387 hasAuthorship W2011766387A5005341632 @default.
• W2011766387 hasAuthorship W2011766387A5010205635 @default.
• W2011766387 hasAuthorship W2011766387A5010392419 @default.
• W2011766387 hasAuthorship W2011766387A5012870792 @default.
• W2011766387 hasAuthorship W2011766387A5012938382 @default.
• W2011766387 hasAuthorship W2011766387A5013907733 @default.
• W2011766387 hasAuthorship W2011766387A5037618983 @default.
• W2011766387 hasAuthorship W2011766387A5048265991 @default.
• W2011766387 hasAuthorship W2011766387A5050283922 @default.
• W2011766387 hasAuthorship W2011766387A5052742879 @default.
• W2011766387 hasAuthorship W2011766387A5054454647 @default.

• next